CHAD M. ROBINS - 07 Mar 2022 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
CEO and Chairman, Director
Signature
/s/ Chad Robins by Eric Billings, Attorney-in-Fact
Issuer symbol
ADPT
Transactions as of
07 Mar 2022
Net transactions value
-$617,982
Form type
4
Filing time
09 Mar 2022, 18:00:12 UTC
Previous filing
08 Mar 2022
Next filing
08 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise $93,631 +14,815 +0.77% $6.32 1,930,969 07 Mar 2022 Direct F1
transaction ADPT Common Stock Sale $6,110 -500 -0.03% $12.22 1,930,469 07 Mar 2022 Direct F1, F2
transaction ADPT Common Stock Sale $165,052 -14,315 -0.74% $11.53 1,916,154 07 Mar 2022 Direct F1, F3
transaction ADPT Common Stock Options Exercise $93,631 -14,815 -0.76% $6.32 1,930,969 08 Mar 2022 Direct F1
transaction ADPT Common Stock Sale $168,595 -14,815 -0.77% $11.38 1,916,154 08 Mar 2022 Direct F1, F4
transaction ADPT Common Stock Options Exercise $93,631 -14,815 -0.76% $6.32 1,930,969 09 Mar 2022 Direct F1
transaction ADPT Common Stock Sale $184,595 -14,815 -0.77% $12.46 1,916,154 09 Mar 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -14,815 -1.9% $0.000000 785,185 07 Mar 2022 Common Stock 14,815 $6.32 Direct F1, F6
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -14,815 -1.9% $0.000000 770,370 08 Mar 2022 Common Stock 14,815 $6.32 Direct F1, F6
transaction ADPT Stock Option (Right to Buy) Options Exercise $0 -14,815 -1.9% $0.000000 755,555 09 Mar 2022 Common Stock 14,815 $6.32 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2021.
F2 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $12.21 to 12.24, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.21 to 12.20, inclusive.
F4 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $11.27 to 11.55, inclusive.
F5 The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $12.21 to 12.73, inclusive.
F6 The option is fully vested and exercisable.